Home » SHIRE BOOSTED BY CORE DRUGS
SHIRE BOOSTED BY CORE DRUGS
July 28, 2005
Strong growth from its Adderall XR attention disorder treatment helped Shire Pharmaceuticals lift second quarter profits by 25% and up its estimate of revenue growth for the year as a whole. Earnings per share in the three months to June rose from 18.4c to 23c, with revenues up by 32% at $425m. Profits from continuing operations were $116.2m up from $89.5m. Chief executive Matthew Emmens added that revenues for the full year should show low double-digit growth, a slight upgrade on its earlier estimate.
ShareCast (http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=516684)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct